[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571304":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":20,"responsibleParty":36,"collaborators":7,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":7,"eligibilityCriteria":44,"healthyVolunteers":40,"sex":45,"minAge":46,"maxAge":7,"enrollmentInfo":47,"targetDuration":7,"studyType":50,"phases":7,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Federico Pea, MD","PRINCIPAL_INVESTIGATOR",[13,17],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},"CONTACT","0039 051 214 3627","federico.pea@unibo.it",{"name":18,"role":14,"phone":15,"phoneExt":7,"email":19},"Milo Gatti, MD","milo.gatti2@unibo.it",[21],{"facility":5,"status":22,"city":23,"state":7,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"RECRUITING","Bologna","40138","Italy","IT",{"type":28,"coordinates":29},"Point",[30,31],11.33875,44.49381,{"lat":31,"lon":30},[34,35],{"name":10,"role":14,"phone":15,"phoneExt":7,"email":16},{"name":18,"role":14,"phone":15,"phoneExt":7,"email":19},{"type":37,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100571304","impact-of-a-tdm-guided-ecpa-program-for-optimizing-pharmacodynamic-target-attainment-of-continuous-infusion-beta-lactam-based-regimen-100571304",false,"NCT06718517","Impact of a TDM-guided ECPA Program for Optimizing Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam-based Regimen","Impact of a TDM-guided ECPA Program for Optimizing Pharmacodynamic Target Attainment of Continuous Infusion Beta-lactam-based Regimen on Clinical Outcome in Orthotopic Liver Transplant Recipients With Documented Gram-negative Infections","Inclusion Criteria:\n\n1. adult OLT recipients (age ≥ 18 years);\n2. documented Gram-negative infections occurring in the first 90 days after transplantation;\n3. treatment with beta-lactam based-regimens;\n4. signed informed consent.\n\nExclusion Criteria:\n\n1. patients receiving beta-lactam-based regimens for less than 48 hours;\n2. patients with isolation of a Gram-negative resistant to all available beta-lactam classes;\n3. patients on palliative care and\u002For not resuscitation order.","ALL","18 Years",{"count":48,"type":49},65,"ESTIMATED","OBSERVATIONAL","Previous studies have clearly demonstrated a significant impact of optimised antibiotic therapy based on a TDM-guided approach in reducing the clinical and microbiological failure rate and in improving the achievement of an optimal pharmacokinetic\u002Fpharmacodynamic target. However, no study has yet evaluated this aspect in the specific scenario of liver transplant patients with documented infections with Gram-negative pathogens.",[53],"Liver Transplant Infection",[55,56,57,58,59,60],"Liver transplant","Beta-lactams","Gram-negative infections","PK\u002FPD target attainment","Clinical outcome","Inflammatory biomarkers","2024-12-01",{"date":63,"type":64},"2024-12-05","ACTUAL",{"date":66,"type":64},"2024-08-28",{"date":68,"type":49},"2026-12-31",{"name":5,"class":6},1]